Insider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells 8,064 Shares of Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 8,064 shares of Genelux stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $3.50, for a total value of $28,224.00. Following the completion of the transaction, the insider now directly owns 1,255,730 shares in the company, valued at $4,395,055. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Stock Performance

GNLX opened at $3.45 on Thursday. Genelux Co. has a 1 year low of $3.26 and a 1 year high of $40.98. The stock’s 50 day simple moving average is $5.86 and its 200-day simple moving average is $10.95.

Genelux (NASDAQ:GNLX) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). As a group, equities analysts expect that Genelux Co. will post -0.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. HC Wainwright dropped their price target on Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Benchmark reaffirmed a “speculative buy” rating and issued a $30.00 price target on shares of Genelux in a research report on Wednesday, April 3rd.

Institutional Trading of Genelux

A number of institutional investors and hedge funds have recently modified their holdings of the company. Amalgamated Bank boosted its stake in Genelux by 250.8% in the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock valued at $26,000 after buying an additional 770 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Genelux by 216.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock valued at $41,000 after buying an additional 2,021 shares in the last quarter. Barclays PLC boosted its stake in Genelux by 516.4% in the 3rd quarter. Barclays PLC now owns 3,384 shares of the company’s stock valued at $83,000 after buying an additional 2,835 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Genelux by 89.5% in the 3rd quarter. New York State Common Retirement Fund now owns 5,495 shares of the company’s stock valued at $135,000 after buying an additional 2,595 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in Genelux by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock valued at $87,000 after buying an additional 1,573 shares in the last quarter. 37.33% of the stock is currently owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.